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MiR-155, a potential serum marker of
extramammary Paget’s disease
Hao Guo1, Rui-Qun Qi1, Jie Sheng2, Chang Liu3, Hang Ma3, He-Xiao Wang1, Jiu-Hong Li1, Xing-Hua Gao1,
Yin-Sheng Wan4 and Hong-Duo Chen1*

Abstract
Background: Extramammary Paget’s disease (EMPD), a rare skin malignancy with non-specific manifestations, is
often misdiagnosed as eczema of scrotum or tinea cruris. Although the diagnosis of EMPD could be confirmed by
biopsy, it can be delayed as patients are reluctant to receive invasive operations. Herein, we investigated the serum
miRNA expressions of EMPD patients and compared to that of the eczema of scrotum or tinea cruris patients as
well as health volunteers for potential diagnostic markers for EMPD.
Methods: Altogether 45 subjects including 16 patients diagnosed with EMPD, 12 patients diagnosed with eczema
of scrotum or tinea cruris and 17 healthy volunteers were enrolled in this study. Serum from all of subjects were
collected to identify miRNAs (by miRNA array global normalization, RT-PCR validation, and receiver operating
characteristic curve analysis) that could be potential diagnostic markers for EMPD.
Results: The miRNA array analyses revealed that the expressions of 37 miRNAs from the EMPD patients were
different (change ≥4-fold) from health volunteers. Among these miRNAs, the expression of miR-155 was
significantly increased (p < 0.01) in the EMPD patients as compared with that of the health volunteers and the
eczema of scrotum or the tinea cruris patients (no difference between these two control groups). In addition,
receiver operating characteristic (ROC) curve analysis showed that diagnostic capacities (defined as the area under
curve of ROC) of miR-155 are 0.85 (as compared with health volunteers group) and 0.81 (as compared with the
eczema of scrotum or the tinea cruris patients group), respectively.
Conclusion: The serum miRNA expression of gene miR-155 in the EMPD patients was differentiated from that of
other subjects warranting further validation of miR-155 as a diagnostic marker of EMPD.
Keywords: General dermatology, MiR-155, Extramammary Paget’s disease

Introduction
Extramammary Paget’s disease (EMPD) is a rare cutaneous malignancy that affects apocrine-rich areas such as
the vulva, penis, scrotum and perianal area [1]. Its clinical
manifestations are not specific and can be presented as
erythematous patches, plaques or erosions, occasionally
with adherent crust [2]. Patients may also experience
symptoms of pruritus and tenderness [1–3]. Therefore,
EMPD is also known as “eczematoid carcinoma” as it can
be misdiagnosed as eczema of scrotum (ECZ) or tinea
cruris (TIN) at the early stage. In the clinic, without
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proper histopathological examinations, EMPD patients
with unspecific manifestations are often misdiagnosed as
ECZ/TIN. Topical treatments may relieve symptoms of
ECZ/TIN (such as pruritus), it gives an illusion of false
improvement which leads to further delayed diagnosis of
EMPD. It is reported that EMPD has a median delayed
diagnosis of 2 years due to the aforementioned reasons [2, 4]. Although biopsy is the gold standard for
diagnosis of EMPD, some suspected EMPD patients
are reluctant to receive biopsy due to the invasiveness
of the procedure. Therefore, investigations of noninvasive markers to improve the diagnosis of EMPD are
of great research interest.
MicroRNAs (miRNAs) are a class of 19–25-nucleotide
noncoding RNAs that have been implicated in the
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regulations of various cellular processes [5]. Some miRNAs have been reported to have significant correlations
with cancer development and progression. They have
been investigated as circular markers of many malignancies [6, 7]. In our previous study, miRNAs including
miR-31, miR-375 and miR-31* were overexpressed in
EMPD tissue as compared to normal keratinocytes and
normal apocrine glands (the historical origin of EMPD)
using laser-capture microdissection in frozen tissues
from 12 EMPD patients [8]. However, to date, neither
serum miRNAs of EMPD have been investigated, nor
serum markers were validated in clinics for the diagnosis
of EMPD. Herein, we investigated expressions of miRNAs from human subjects using miRNA array analyses
to identify specific miRNAs for potential diagnostic
serum markers of EMPD.

Patients and methods

excluded in this study. All of the patients and healthy
volunteers came from the region of northeastern of
China.
Enrolled healthy volunteers (normal group) were
excluded from any malignancies, allergic dermatisis,
infections and certain internal diseases through physical
examinations as normal control.
EMPD patients (EMPD group), diagnosed via histopathological examination, were ruled out of diseases including allergic dermatisis, infections, EMPD metastasis
and other malignancies via comprehensive examinations
(including chest CT, abdominal & urinary system B
ultrasonic and enteroscope).
Eczema of scrotum or tinea cruris patients (ECZ/TIN
group) were diagnosed via comprehensive physical and
dermatological examinations (including blood routine,
total IgE and fungus microscope examination). They
were ruled out of other infections and malignancies via
comprehensive examinations.

Study population

The study was approved by ethics committee of No. 1
Hospital of China Medical University (No. AF-SOP07-1.0-01).
Patients and healthy volunteers were enrolled from
No.1 Hospital of China Medical University from 2014 to
2017. Healthy volunteers (17), EMPD patients (16),
ECZ/TIN patients (12) were archived and enrolled in
this study. Clinical basic characteristics of the volunteers
and patients were summarized in Table 1. To minimize
the heterogeneity in our enrolled cases, females were

Table 1 Demographics and clinical features

RNA isolation

Blood samples were collected form enrolled patients and
volunteers. Serum from blood samples were prepared
through a centrifuge at 4000 rpm for 15 min. Collected
serum samples were extracted for total RNA including
miRNAs by Qiagen miRNeasy Micro Kit accordingly to
the manufacture’s protocol with minor modifications.
Briefly, serum from each sample was lysed with QIAzol
lysis reagent and then 100 uL of chloroform were added.
Next, samples were centrifuged for 15 min at 12000 xg
at 4 °C. The upper aqueous phase of each sample was
transferred and 1.5 times of volumes of 100% ethanol
were added. Then mixtures went through the RNeasy
Micro spin column and 40 ul RNase free water were
used to elute. The volume of each sample was reduced
to 15–20 ul by vacuo. RNA quantity (15–20 ng/ul) and
quality (OD 260/280 was approximately 1.0 with a peak
at 270 nm) were assessed with the ThermoScientific
NanoDrop 2000 (Thermo Fisher Scientific, Inc., Franklin,
MA, USA).

Characteristics

Normal

EMPD

ECZ/ TIN

Sample size, n

17

16

12 (nTIN = 7; nECZ = 5)

Male

17

16

12

Female

0

0

0

61.8 ± 8.7

63.7 ± 8.4

58.2 ± 11.7

Penis

1

0

TaqMan low-density array miRNA qRT-PCR

Scortum

5

5

Scortum & penis

1

0

Due to the limited RNA obtained from serum, a
pre-amplification step was added as per manufacture’s
protocol when miRNA array was performed in 2
samples of normal and 2 samples of EMPD in both
groups for screening.
The reversed transcription of RNA was prepared using
the TaqMan MiRNA Reverse Transcription Kit and
TaqMan MiRNA Multiplex RT Assays (human pool A;
V2.1). RNA (3 ul) was added to each reaction and
RT-PCR was carried on an ABI Veriti Thermal cycler
(Applied Biosystems, Foster City, CA, USA). The
product (2.5 ul) from each reaction was pre-amplified as

Gender, n

Age, years
Primary site, n

Gorin (including thigh)

5

4

Scortum & gorin

4

3

< 10

2

1

10–19

4

4

20–29

6

4

29–39

3

3

> 39

1

0

Size of lesion (cm2), n
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per manufacturer’s protocol with the Megaplex PreAmp
Primers (10×), Human pool A (V2.1) and TaqMan
PreAmp Master Mix (2×). Then miRNA expression was
profiled with TaqMan Human MicroRNA array card A
(V2.1), performed on a 7900HT Fast Real-Time PCR
System (Applied Biosystems, Foster City, CA, USA),
using the manufacturer’s recommended protocol.
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Global normalization

Raw cycle threshold (Ct) values were calculated using
SDS 2.3 and RQ manager 1.2 software (Applied Biosystems, Foster City, CA, USA) using default baselines and
threshold settings. All the Ct values were exported into
StatMiner® 4.2 (Integromics® Inc., Philadelphia, PA,
USA) for global normalization. The miRNAs detected in

Fig. 1 EMPD’s procedure chart and result of miRNA array. a Flow diagram of how our serum miRNA array was performed. b MiRNA expression
profiles. MiRNA expressions of two pairs of normal and healthy volunteers and EMPD patients were profiled using TaqMan Human MicroRNA
array card A (v2.1). The cycle threshold (Ct) values were obtained with SDS 2.3 and RQ manager 1.2 software (Applied Biosystem) and analyzed
with RealTime StatMiner® 4.2 software (Integromics, Inc.). The -ΔCt was calculated and heat map analysis was performed with Excel. A greenyellow-red color scale (− 6.0 to 12.7) depicts normalized miRNAs expression level based on global normalization. c Differently expressed miRNAs
between normal and EMPD, using -ΔCt from 2 decreased miRNAs (miR-122, miR-375) and 3 most significantly increased miRNAs (miR-155,
miR-495, miR-652)
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all of the samples were used for global normalization.
The mean Ct value of each individual sample was
calculated by the global normalization, and subtracts
the Ct value from each miRNA of the same sample
to obtain the ΔCt value. The miRNAs that were
expressed in all samples were considered meaningful
for further data analysis. Heat-map analysis was performed using ΔCt with hierarchical clustering using
miRNAs expressed in all 4 samples. Average ΔCt of
normal and EMPD were calculated separately, the
ΔΔCt (ΔCtNORMAL-ΔCtEMPD) was also calculated for
further study.
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the variations, and the overall miRNA gene expression
profiles between different individuals were consistent
(Fig. 1b). Some miRNAs showed difference between normal and EMPD groups [miRNAs (|ΔΔCt| ≥ 2)] and were
defined as potentially different. Expression of 2 miRNAs
were down-regulated and 35 miRNAs were up-regulated
(Table 2).
Table 2 Differentially expressed miRNAs in array
miRNAs

ΔCtNormal-1 ΔCtNormal-2 ΔCt EMPD-1 ΔCt EMPD-2 ΔΔCt

hsa-miR-375

−1.2

− 1.6

0.6

1.6

−2.5

hsa-miR-122

−2.7

−3.8

−1.4

0.3

−2.7

RT-PCR

hsa-miR-155

−2.0

−3.8

−10.7

−12.7

8.8

After significantly different expressed miRNAs were
obtained, specific RT-PCR analyses were performed
(15 normal, 14 EMPD as well as 12 ECZ/TIN). The
RNA was reverse transcribed using the TaqMan
MiRNA Reverse Transcription Kit. Then RT- PCR
was performed following protocols provided by
TaqMan.

hsa-miR-652

4.7

4.2

−0.5

−0.1

4.8

mmu-miR-495

−1.3

−1.2

−6.5

−5.3

4.7

hsa-miR-486

0.8

0.1

−2.2

−4.1

3.6

hsa-miR-376a

4.7

3.0

0.8

0.4

3.3

hsa-miR-423-5p −0.4

0.8

−0.5

−5.2

3.11

hsa-miR-133a

3.0

4.9

0.7

1.2

3.0

hsa-miR-20a

−5.2

−4.6

−8.2

−7.7

3.0

hsa-miR-181a

1.7

4.6

0.6

0.1

2.79

hsa-miR-744

3.2

1.5

−0.7

−0.1

2.75

hsa-miR-660

−0.3

0.0

−3.5

−2.1

2.63

hsa-miR-29a

−0.1

−1.2

−3.1

−3.4

2.6

3.0

−0.8

0.0

2.6

−0.1

0.9

−2.4

−1.9

2.6

hsa-miR-590-5p −0.7

1.6

−2.3

−1.7

2.4

Statistical analysis

For all samples in RT-PCR, cycle threshold (Ct)
values were obtained with SDS 2.3 and RQ manager
1.2 software (Applied Biosystems, Foster City, CA,
USA). Expressions of miRNAs were calculated with
StatMiner® 4.2 (Integromics® Inc., Philadelphia, PA,
USA) using –ΔCt* [−(Ct-Ctmir-374-5p)] of each sample.
Bonferroni’s Multiple Comparison Test was used to
compare the (-ΔCt*) value among the three groups.
P-value < 0.05 are considered significantly different
between two groups. Receiver Operating Characteristic (ROC) curve analysis was then performed using
the differentially expressed miRNA. Scattergraph and
ROC curve analysis were both performed by GraphPad Prism.

Results
MiRNA array and global normalization

The miRNA gene expression profiles were obtained
from two normal and two EMPD patients (flow diagram
showed how serum miRNA arrays analyses shown in
Fig. 1a). A total of 255 miRNAs were detected in the
TaqMan® Array MicroRNA human card A. In average
166 miRNAs were detected per sample, and 105 miRNAs were detected in all the samples. For each sample,
the global mean value of the expression of the 105 miRNAs was calculated, then the difference (ΔCt) between
the expression of each individual miRNA in this given
sample and the global mean was obtained. Heat-map
analysis showed that most of miRNAs’ expressions were
relatively consistent across different samples. The
heat-map indicated that global normalization reduced

hsa-miR-142-5p 1.4
hsa-miR-145

hsa-miR-106a

−5.4

−5.9

−8.0

−8.0

2.4

hsa-miR-328

0.3

1.5

−1.2

−1.7

2.4

hsa-miR-140-3p 3.2

3.0

1.1

0.4

2.35

hsa-miR-194

1.3

−0.8

−0.4

2.4

2.2

hsa-miR-532-3p 2.9

2.4

0.9

0.0

2.2

hsa-miR-23a

−0.1

0.0

−2.4

−2.1

2.2

hsa-miR-223

−10.6

−10.1

−12.8

−12.3

2.2

hsa-miR-26b

−2.6

−1.5

−4.6

−3.8

2.2

hsa-miR-17

−6.0

−6.0

−8.1

−8.3

2.2

hsa-miR-185

0.0

1.9

−1.3

−1.0

2.1

hsa-miR-20b

−3.2

−2.6

−4.8

−5.2

2.1

hsa-miR-454

−1.6

0.0

−2.6

−3.1

2.1

hsa-miR-143

1.4

3.4

−0.6

1.2

2.1

hsa-miR-191

−5.2

−4.2

−6.7

−6.7

2.0

hsa-miR-15b

−1.4

0.3

−2.0

−3.1

2.0

hsa-miR-130b

0.4

0.9

−1.7

−1.0

2.0

hsa-miR-200c

4.6

3.9

2.6

2.0

2.0

hsa-miR-301

1.0

1.9

−0.1

−1.0

2.0

hsa-miR-222

−5.5

−5.3

−7.8

−6.9

2.0

hsa-miR-484

−5.7

−5.1

−7.0

−7.7

2.0
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MiR-155 was found obviously up-regulated in EMPD serum

ROC curve analysis of serum miR-155 of EMPD

The 2 down-regulated miRNAs (miR-122 and miR-375)
and 3 up-regulated miRNAs with largest |ΔΔCt|
(miR-155, miR-495, and miR-652) were selected for
further validation (Fig. 1c).
Then RT-PCR of the above 5 miRNAs among normal,
EMPD as well as ECZ/TIN groups (the differential diagnosis group) were performed. Bonferroni’s Multiple
Comparison Test was carried out among three groups.
Expression levels of miR-122, miR-375, miR-495 and
miR-652 showed no difference among three groups
(Fig. 2). Expression of miR-155 significantly increased in
the EMPD group as compared to other groups and there
is no difference between normal and ECZ/TIN (Fig. 2c)
groups. We combined data from two common differential diagnosis diseases, ECZ/TIN, together as one group
due to the limited patient number we enrolled.

The expression of miRNA-155 showed significant increase as compared to normal and common differential
diagnosis diseases, which suggested that miRNA-155
may be a potential serum marker of EMPD diagnosis.
Furthermore, ROC curve analysis of miR-155 was established based on three groups. Our results showed that
miR-155 could accurately distinguish patients of EMPD
from healthy volunteers with AUC (area under curve) of
0.85 (Fig. 2f ). Similarly, this marker could distinguish
patients with EMPD from patients with ECZ/TIN with
AUC of 0.81 (Fig. 2g).

Discussion
Paget’s disease is a rare cutaneous intraepithelial
malignancy characterized by Paget cells (large cytoplasm
and mucin rich adenocarcinoma cells) [9]. It has two

Fig. 2 EMPD’s expression of specific miRNAs and ROC curve. a-e The expression levels (-ΔCt) of miR-122, miR-375, miR-155, miR-495 and miR-625
in normal, EMPD and ECZ/TIN, using –ΔCt’ [−(Ct-Ctmir-374-5p)] among normal (n = 15), EMPD (n = 14) and ECZ/TIN groups (n = 12) (**p < 0.01,
***p < 0.0001). ROC curve of serum miR-155 in EMPD patients. f using normal as control; g using ECZ/TIN as control
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subtypes according to the affected anatomic location:
mammary Paget’s diseases and EMPD. The mammary
Paget disease was first found by James Paget in 1874, it
was reported as an intraepithelial breast carcinoma and
suggested that the pattern may be found in other parts
[10]. EMPD was first described by Crocker in 1888 [10].
EMPD has unspecific manifestations and can be misdiagnosed as ECZ/TIN. It also has a high recurrence rate
after surgery treatment due to the subclinical extension
and the multifocal feature [2, 11–14]. Therefore, researches have been focusing on investigations of serum
markers aiming to improve the diagnosis and prognosis
[15, 16]. Circular miRNAs have been extensively investigated as biomarkers helping with the diagnosis during
the past decade [17]. For this current study, a major
finding was that miR-155 was significantly increased in
the serum of EMPD patients. We sought to identify several promising serum markers, and use the combination
of serum markers as a diagnostic method. However, the
results of miR-122, miR-375, miR-495 and miR-625
showed no difference between normal and EMPD
groups which were differentially expressed in array. This
might be caused by the heterogeneity among patients
and the limited number enrolled in the array analyses.
Based on our previous studies, the serum miRNAs
varied immensely among patients [18]. This study was
performed on small sample size, and all the other
published serum markers of EMPD were based on
small sample size research due to the rarity of the
disease [15, 16]. We suggest the specific expressed
miR-155 can be used and/or in combination with
other serum markers including CEA and Cytokeratin
19 fragment 21–1 to improve the diagnosis after further
validation [15, 16].
In Fig. 2, three EMPD patients showed relative low expression of serum miR-155. However, no specific clinical
features in age, tumor site, tumor size, tumor depth, and
appendages involvement in pathology were observed in
these patients. It is reported that > 93% of mammary
Paget’s diseases was associated with underlying ductal
breast cancer [19]. In addition, 29% of EMPD patients
were associated with internal malignancies including
breast cancer, colorectal cancer, prostate cancer, bladder
cancer and gastric cancer [20]. Therefore, EMPD is
likely associated with internal malignancies with
contiguous epithelium [2]. The EMPD in perianal area is
more likely associated with underlying colorectal cancer,
while EMPD in scrotum or vulvar have a high incidence
of prostate cancer [2].
A large body of evidence reveals that EMPD is an
adenoma the histogenetic origin from apocrine glands
[1, 21–27]. In histological study, mammary glands and
apocrine glands have the same apocrine secretion pattern. Some immunohistochemical marker of EMPD are
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also positive in specific type of breast cancer such as human epidermal growth factor receptor 2 (Her2/erbB2),
carcinoembryonic antigen (CEA), cytokeratin 7 (CK7)
and gross cystic disease fluid protein 15 (GCDFP15)
[1, 23, 28–32]. These markers are also positive in
other cancers such as prostate adenocarcinoma
(Her2/erbB2, CK7 and GCDFP15) [33–35] and colon
cancer (Her2/erbB2 and CEA) [34, 36, 37]. The above
evidence suggested that EMPD may have common
features with breast cancer, prostate cancer and colon
cancer as they are all adenocarcinomas and have a
high incidence of co-existence. In our current study,
we found the expression of miRNA-155 significantly
increased as compared to healthy volunteers and common
differential diagnosis diseases. In our previous study, we
performed miRNA arrays between EMPD tissue and
peripheral normal skin from the fresh frozen tissue of the
same patient using laser-capture microdissection [8]. Data
from that study showed that miR-155 was overexpressed
in the tissue EMPD (AVE-△Ct EMPD = − 19.96) compared to
peripheral normal skin (AVE-△Ct CON = − 22.97) in array
[8]. The consistent findings suggest the increased serum
miR-155 may be derived from the EMPD tumor tissue.
MiR-155 is also overexpressed in the tissue and serum of
multiple types of cancers including breast, prostate, and
colon cancers [38–44]. MiR-155 is now considered as one
of the most familiar onco-miRNAs especially in breast
cancer. The overexpressed serum miR-155 in breast cancer has been varifed by different research groups [38–40].
Our result provides new insights that these malignancies
may share common features. However, further investigations on the linkage between miR-155 and EMPD are
warranted.

Conclusion
In summary, this is the first study on the serum miRNA
expression profile of EMPD patients. Biomarker miR-155
was significantly increased in EMPD patients as compared
with the two control groups (health volunteers and ECZ
or TIN patients; no difference between these two controls). Therefore, miR-155 could be targeted as a potential
diagnostic marker to improve the diagnosis of EMPD
warranting further validations.
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